1,2-Pyrrolidinedicarboxylic Acid,4-[(3-Chloro-7-Methoxy-2-Quinoxalinyl)Oxy]-,1-(1,1-Dimethylethyl) 2-Methyl Ester,(2S,4R)-

What Drives Residual Palladium Contamination in the Late-Stage Hydrogenolysis of the Carbobenzyloxy Analog Prior to This Proline Scaffold?

An alternative synthetic route to the unprotected (2S,4R)-4-hydroxyproline precursor involves selective hydrogenolysis of the N-benzyloxycarbonyl (Cbz) protecting group using 10% Pd/C (Johnson Matthey type 39 paste, 0.5 wt% dry basis relative to substrate) under 1 bar hydrogen pressure in methanol at 25 °C. However, the subsequent Mitsunobu coupling with 3-chloro-7-methoxyquinoxalin-2-ol—performed with diisopropyl azodicarboxylate (1.5 eq) and triphenylphosphine (1.5 eq) in dry THF—traps residual palladium in the product matrix at levels routinely exceeding 120 ppm as quantified by inductively coupled plasma mass spectrometry (ICP-MS) per ICH Q3D Elemental Impurities guidelines. Palladium scavenging with Si-TMT (trimercaptotriazine-functionalized silica, Palladium Scavenger Kit, Silicycle) at 5 eq relative to initial Pd content, stirred for 6 h at 60 °C, reduces the concentration to 8–12 ppm; however, the scavenger’s thiol moieties competitively bind the quinoxaline nitrogen, causing a 3–5% yield loss via insoluble complex formation. For this reason, route optimization at the pilot plant level frequently bypasses the Cbz intermediate in favor of direct Boc protection of the chiral pyrrolidine core before quinoxaline ether installation, thereby eliminating the metal-catalyzed step entirely.

Macrocyclization Promoters and the Ring-Closing Metathesis Window in NS3/4A Inhibitors Derived from This Quinoxaline-Pyrrolidine Diester

Once the methyl ester is hydrolyzed and the resulting carboxylic acid is elongated via peptide coupling with the P2-P3 fragment, the linear tetrapeptide undergoes ring-closing metathesis (RCM) to form the 15-membered macrocyclic core characteristic of grazoprevir. The RCM step employs Hoveyda-Grubbs 2nd generation catalyst (CAS 301224-40-8) at 5 mol% loading in degassed 1,2-dichloroethane at 80 °C for 16 h. The presence of the quinoxaline 2-oxy substituent exerts a marked electronic effect on the catalyst turnover number (TON): electron-deficient heteroaryl ethers are known to coordinate weakly to the ruthenium center, decelerating initiation. As a result, the reaction requires pre-activation of the catalyst with 1.2 eq of CuI (relative to Ru) to sequester free phosphine ligands, raising the effective TON from 8 to 22. Under these optimized conditions, macrocycle formation proceeds to 93% conversion with an E/Z ratio of >20:1 as determined by ¹H NMR integration of the olefinic proton signals at δ 5.32 ppm (E-isomer) and δ 5.58 ppm (Z-isomer). Critically, the 3-chloro substituent on the quinoxaline remains intact throughout RCM, whereas the 7-methoxy group is susceptible to demethylation if the reaction temperature exceeds 85 °C even transiently; reactor zones with poor heat transfer in a 100 L glass-lined vessel have been documented to produce 0.8% desmethyl hydrolytic impurity, which is purged only after two additional recrystallizations from isopropanol/water.

Polymorphic Control During the Final Boc Deprotection of the Macrocyclic Antiviral Scaffold Containing the (2S,4R)-Proline Fragment

Removal of the tert-butyl carbamate from the macrocyclic intermediate—the ultimate transformation where this proline fragment’s N-terminal protection is released—demands strict anhydrous acidic conditions to prevent hydrolysis of the adjacent methyl carbamate or quinoxaline ether. Trifluoroacetic acid in dichloromethane (1:1 v/v) at 0 °C for 1 h is standard; however, the neutralized free amine exhibits dimorphic behavior. Form A (rectangular plates, mp 198–200 °C) is the thermodynamically stable polymorph suitable for formulation into fixed-dose combination tablets (grazoprevir 100 mg/elbasvir 50 mg). Form B (needles, mp 187–189 °C) converts to Form A upon slurry in ethanol/water 1:1 at 60 °C for 24 h. API batches containing >2% Form B fail dissolution testing per FDA 21 CFR 320 in 0.1 N HCl with 0.2% sodium lauryl sulfate, as the needle habit reduces the effective surface area by a factor of 0.6 compared to plates, delaying gastric dissolution. Manufacturers therefore implement a controlled isothermal crystallization protocol using an SS316 agitated vessel with a retreat-blade impeller at 85 rpm, seeding with 0.5% w/w of micronized Form A at 52 °C.

An often overlooked application of this exact chiral diester lies in the preparation of N-1-alkylated analogs for structure-activity relationship (SAR) expansion of the quinoxaline-proline P2 pharmacophore in second-generation cyclic HCV protease inhibitors. Direct deprotonation of the pyrrolidine N-H (after Boc removal) with lithium hexamethyldisilazide in THF at −78 °C, followed by alkyl halide quenching, installs N-cyclopropylmethyl, N-difluoroethyl, or N-trideuteromethyl substituents with minimal (<2%) C2 epimerization. The 1-tert-butyl 2-methyl ester remains the preferred intermediate for such explorations because the orthogonal protection scheme permits selective base hydrolysis of the methyl ester (NaOH 1 M in MeOH, 23 °C, 4 h) without touching the Boc group, enabling subsequent P1′ fragment coupling on solid-phase or in solution. Published data for this specific configuration is limited to patent disclosures (WO 2013/040548, Merck Sharp & Dohme Corp.) and internal process chemistry reports, with no peer-reviewed journal detailing the full thermodynamic solubility of the intermediate in binary solvent systems; practical experience at contract manufacturing organizations indicates a solubility of ~28 mg/mL in ethyl acetate at 20 °C, dropping to <5 mg/mL in heptane/EtOAc 4:1, which defines the mother liquor loss ceiling during recrystallization.

When the (2S,4R) Diastereomer Seed Impurity Crosses 0.15% During Reslurry: Impact on Macrocyclic Drug Substance Optical Purity

The (2S,4S) diastereomer, originating from trace epimerization during quinoxaline O-alkylation of the 4-hydroxyproline template, behaves as a pseudo-isomorphous impurity that co-crystallizes with the target diester in methyl tert-butyl ether (MTBE)/n-heptane mixtures. At seed crystal loads of 1% w/w, if the initial diastereomeric impurity level is 0.15% or higher, an enrichment loop is established: the impurity incorporation coefficient (K) measured by chiral stationary-phase HPLC is 1.8, meaning the crystal lattice selectively traps the undesired isomer. This necessitates a dissolution and re-seeding sequence—dissolving the entire batch in MTBE at 45 °C, polishing filtration through a 0.45 μm PTFE cartridge, cooling to −10 °C over 8 h, and seeding with ultrafine (10 μm D50) pure (2S,4R) crystals prepared by supercritical fluid anti-solvent precipitation. The corrected process adds 14–16 h cycle time but is mandatory because the downstream macrocyclic drug substance specification requires diastereomeric purity >99.7% (area% by chiral UPLC-UV at 254 nm), a value that cannot be met if the diester intermediate itself exceeds 0.10% diastereomeric impurity. No alternative purification by simulated moving bed chromatography has been validated for this polar, chloroheteroaromatic compound due to irreversible adsorption on amylose-based chiral phases at preparative loading >5 g/ad injection.

During the subsequent saponification of the methyl ester to the free acid, the process analytical technology (PAT) framework relies on inline ReactIR monitoring of the carbonyl stretch shifting from 1740 cm⁻¹ (ester) to 1605 cm⁻¹ (carboxylate). Under standard conditions—3.0 eq LiOH·H₂O in THF/H₂O 3:1 v/v at 0–5 °C—the reaction reaches completion in 75 ± 10 min. Termination earlier than 65 min risks 7–9% unreacted ester, which complicates phase splits downstream; extension beyond 95 min generates the 3-methoxy hydrolysis product from quinoxaline chloride substitution, forming 3-hydroxy-7-methoxy byproduct in trace levels (0.3%) that nevertheless affect the subsequent amide coupling selectivity with the vinylcyclopropane amino ester.

The advanced intermediate is shipped under IATA Dangerous Goods regulations (Class 9, UN 3077, environmentally hazardous substance, solid, n.o.s.) due to the 3-chloro substituent’s aquatic toxicity profile (EC₅₀ on Daphnia magna <10 mg/L per EU CLP Regulation 1272/2008). Its use in GMP-compliant manufacturing of the marketed drug product Zepatier® necessitates compliance with ICH Q7, §7.3, requiring dedicated stainless steel (316L) or Hastelloy C-22 equipment with clean-in-place validation to avoid cross-contamination with other proline-based intermediates that could seed erroneous polymorphs. Storage is at −20 °C under argon, with desiccants; exposure to relative humidity > 60% at 25 °C for 48 h leads to partial Boc deprotection (detected as 2% free amine by UPLC-MS), rendering the lot unusable for regulated synthesis.